• Merck’s Continuous Process Improvement

    Continuous improvement doesn’t just depend upon Lean principles and/or zero-based budgeting. It depends upon people inspired by a culture that values learning, promotes problem-solving skills, and strives toward big goals by making small improvements every day.

  • International Incentives: Are They All They’re Cracked Up To Be?

    Economic development agencies approach many pharmaceutical companies with incentives that included a wide range of grants, tax incentives, logistics help, and other enticements like streamline bureaucracy. 

  • Pharma Partnering: Two Views From China

    Naturally, any potential partners must be vetted, but when working in regions that lack a history of pharmaceutical regulation, local partnering can be fraught with peril. China is a good example.


  • The Business Case For Pharmaceutical Serialization

    Aside from regulatory compliance, pharmaceutical companies say the main benefit of serialization will be its support of anti-counterfeiting and diversion efforts, which translates to patient safety.

  • Fostering Asian Collaborations For Pharma Innovations

    Astrazeneca’s collaboration with Asia extends their opportunity in pharmaceutical R&D and commercialization, because Asia lacks the entrenched drug development bureaucracy, which provides a relatively clean slate for pharma innovation.

  • Planning Serialization For Pharmaceutical Manufacturers

    The mandates to serialize all pharmaceutical products are as challenging for pharmaceutical manufacturers as the Y2K situation was to computer software engineers in 1999. Unlike the computer situation, however, the pharmaceutical industry has no defined protocols or solutions.

  • Logistics Improving In Emerging Markets

    Whether there for clinical trials, manufacturing, or market share, life sciences companies entering emerging and developing regions for the first time “tend to overlook the challenges associated with security, regulations, and the unique nature of the supply chain,” notes Bill Hook, VP of global strategy for UPS Healthcare Logistics.

  • Partnerships In Cold Chain Delivery

    Against a backdrop of increasing regulations, fuel costs, and delays clearing customs (especially in developing regions), life sciences companies are turning to their logistics service providers (LSPs) to smooth the way. The providers are responding by forging deeper, more collaborative relationships with their shippers and by designing cold chain services with pharmaceuticals in mind.

Gail Dutton

Gail Dutton

Gail Dutton has covered the biotech industry since soon after its inception, focusing on the intersection of business and science.